CTOs on the Move

Nohla Therapeutics

www.nohlatherapeutics.com

 
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Nohla Therapeutics raised $20M on 12/03/2015
Nohla Therapeutics raised $43.5M on 11/30/2016
Nohla Therapeutics raised $45M on 05/15/2018
Nohla Therapeutics raised $49M on 07/12/2018
Nohla Therapeutics raised $11M on 07/12/2018

Similar Companies

DFM

DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Maxim Health Information Services

Maxim Health Information Services is a Gardena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com

Saltwhistle Technology

Saltwhistle Technology is a Chester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Potenza Therapeutics

Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.